Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
PLX 
Protalix Biotherapeutics Inc (PLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/08/2026: PLX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11
1 Year Target Price $11
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 23.43% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 01/08/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 160.84M USD | Price to earnings Ratio 25 | 1Y Target Price 11 |
Price to earnings Ratio 25 | 1Y Target Price 11 | ||
Volume (30-day avg) 1 | Beta -0.25 | 52 Weeks Range 1.32 - 3.10 | Updated Date 01/8/2026 |
52 Weeks Range 1.32 - 3.10 | Updated Date 01/8/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 8.72% | Operating Margin (TTM) 11.94% |
Management Effectiveness
Return on Assets (TTM) 5.53% | Return on Equity (TTM) 12.64% |
Valuation
Trailing PE 25 | Forward PE 10.17 | Enterprise Value 121956702 | Price to Sales(TTM) 2.6 |
Enterprise Value 121956702 | Price to Sales(TTM) 2.6 | ||
Enterprise Value to Revenue 1.97 | Enterprise Value to EBITDA 14 | Shares Outstanding 80421181 | Shares Floating 61352515 |
Shares Outstanding 80421181 | Shares Floating 61352515 | ||
Percent Insiders 10.15 | Percent Institutions 17.52 |
Upturn AI SWOT
Protalix Biotherapeutics Inc
Company Overview
History and Background
Protalix BioTherapeutics Inc. was founded in 1993 as Protalix Ltd. and later became Protalix BioTherapeutics Inc. The company is a biopharmaceutical company focused on the development and commercialization of recombinant proteins produced through its proprietary ProCellExu00ae plant-based expression system. Key milestones include the development of its flagship product, ELELYSO (taliglucerase alfa), for the treatment of Gaucher disease, and strategic partnerships to advance its pipeline.
Core Business Areas
- Recombinant Protein Therapeutics: Development and commercialization of protein-based therapeutics using its ProCellExu00ae plant-based expression system for various rare genetic diseases.
Leadership and Structure
Information on the current leadership team and specific organizational structure is dynamic and best obtained from the company's official investor relations website or SEC filings.
Top Products and Market Share
Key Offerings
- ELELYSO (taliglucerase alfa): A plant-recombinant glucocerebrosidase enzyme replacement therapy (ERT) for the treatment of Gaucher disease. Protalix has historically partnered with Pfizer for the commercialization of ELELYSO outside of Brazil. Market share data for ELELYSO is not publicly detailed as a standalone percentage, but it competes with other ERTs for Gaucher disease. Key competitors include Seres Therapeutics (SERES) with certain indications or research, and established therapies like Cerezyme (imiglucerase) from Sanofi Genzyme and VPRIV (velaglucerase alfa) from Shire (now Takeda).
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the rare diseases and orphan drugs segment, is characterized by high R&D costs, stringent regulatory requirements, and significant unmet medical needs. There is a growing demand for innovative treatments for rare genetic disorders, with a focus on biologics and gene therapies.
Positioning
Protalix Biotherapeutics Inc. is positioned as a specialized biopharmaceutical company leveraging its unique plant-based expression system to develop and produce recombinant protein therapeutics for rare diseases. Its competitive advantage lies in its proprietary ProCellExu00ae technology, which aims for efficient and cost-effective production of complex proteins.
Total Addressable Market (TAM)
The Total Addressable Market (TAM) for treatments for rare genetic diseases is substantial and growing, driven by increased diagnosis, improved understanding of disease mechanisms, and the development of targeted therapies. Protalix Biotherapeutics Inc. targets specific niches within this broad market. Its position is defined by its ability to secure regulatory approvals and market access for its specific drug candidates in their respective disease areas.
Upturn SWOT Analysis
Strengths
- Proprietary ProCellExu00ae plant-based expression system
- Experience in developing recombinant protein therapeutics for rare diseases
- Potential for cost-effective protein production
Weaknesses
- Limited product portfolio
- Reliance on strategic partnerships for commercialization
- High R&D costs and lengthy development cycles inherent in the pharmaceutical industry
- Financial performance can be volatile
Opportunities
- Expansion of product pipeline through internal R&D and potential collaborations
- Leveraging ProCellExu00ae technology for other protein targets
- Growing demand for treatments for rare diseases
- Potential for geographic expansion of approved products
Threats
- Competition from established and emerging biopharmaceutical companies
- Regulatory hurdles and potential delays in drug approvals
- Patent expirations and generic competition
- Pricing pressures and reimbursement challenges
- Changes in healthcare policies and market access
Competitors and Market Share
Key Competitors
- Sanofi (SNY)
- Takeda Pharmaceutical Company (TAK)
- Idorsia Pharmaceuticals Ltd. (IDIA - OTC)
- uniQure N.V. (QURE)
Competitive Landscape
Protalix Biotherapeutics Inc. competes in niche markets for rare diseases, often facing larger, well-established pharmaceutical companies with extensive resources and broader portfolios. Its advantage lies in its specialized technology and focus on specific unmet medical needs, while its disadvantage is its smaller scale and reliance on partnerships.
Growth Trajectory and Initiatives
Historical Growth: Protalix Biotherapeutics Inc.'s historical growth has been characterized by the progression of its drug development pipeline, securing partnerships, and achieving regulatory milestones for its products. Revenue growth has been linked to product launches and collaboration agreements.
Future Projections: Future growth projections for Protalix Biotherapeutics Inc. are contingent upon the success of its ongoing clinical trials, the advancement of its pipeline candidates, and the successful commercialization of new products. Analyst estimates vary and are subject to change based on new developments.
Recent Initiatives: Recent initiatives likely involve advancing late-stage clinical trials, exploring new therapeutic areas, and potentially seeking new strategic partnerships to fund development and expand market reach.
Summary
Protalix Biotherapeutics Inc. is a biopharmaceutical company with a specialized focus on plant-based protein therapeutics for rare diseases. Its proprietary ProCellExu00ae technology offers a potential competitive edge. However, the company faces significant challenges due to its limited product pipeline, reliance on partnerships, and the highly competitive nature of the pharmaceutical industry. Continued success will depend on successful clinical development, regulatory approvals, and effective commercialization strategies.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Protalix Biotherapeutics Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Reputable Financial Data Providers (e.g., Bloomberg, Refinitiv, Yahoo Finance)
- Industry Reports on Rare Diseases and Orphan Drugs
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Financial data and market share estimates are subject to change and may vary between different sources. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Protalix Biotherapeutics Inc
Exchange NYSE MKT | Headquaters Hackensack, NJ, United States | ||
IPO Launch date 1998-05-15 | President, CEO & Director Mr. Dror Bashan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 213 | Website https://www.protalix.com |
Full time employees 213 | Website https://www.protalix.com | ||
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.